{
    "xml": "<topic id=\"PHP96720\" outputclass=\"drug\" rev=\"1.16\" type=\"drug\" namespace=\"/drugs/epoetin-beta\" basename=\"epoetin-beta\" title=\"EPOETIN BETA\">\n<title>EPOETIN BETA</title>\n<body>\n<data name=\"vtmid\">327623006</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_871130604\" title=\"Epoetins\">Epoetins</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34585\" title=\"EPOETINS\" namespace=\"/drug-classes/epoetins\">EPOETINS</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\n</body>\n<topic id=\"PHP96760\" outputclass=\"indicationsAndDose\" rev=\"1.69\" parent=\"/drugs/epoetin-beta\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Symptomatic anaemia associated with chronic renal failure</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By subcutaneous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 20&#8239;units/kg 3 times a week for 4 weeks, increased in steps of 20&#8239;units/kg 3 times a week, according to response at intervals of 4 weeks, total weekly dose may be divided into daily doses; maintenance dose, initially reduce dose by half then adjust according to response at intervals of 1&#8211;2 weeks, total weekly maintenance dose may be given as a single dose or in 3 or 7 divided doses. Subcutaneous route preferred in patients not on haemodialysis. Reduce dose by approximately 25% if rise in haemoglobin concentration exceeds 2&#8239;g/100&#8239;mL over 4 weeks or if haemoglobin concentration approaches or exceeds 12&#8239;g/100&#8239;mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose; maximum 720&#8239;units/kg per week.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By intravenous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 40&#8239;units/kg 3 times a week for 4 weeks, then increased to 80&#8239;units/kg 3 times a week, then increased in steps of 20&#8239;units/kg 3 times a week if required, at intervals of 4 weeks; maintenance dose, initially reduce dose by half then adjust according to response at intervals of 1&#8211;2 weeks. Intravenous injection to be administered over 2 minutes. Subcutaneous route preferred in patients not on haemodialysis. Reduce dose by approximately 25% if rise in haemoglobin concentration exceeds 2&#8239;g/100&#8239;mL over 4 weeks or if haemoglobin concentration approaches or exceeds 12&#8239;g/100&#8239;mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose; maximum 720&#8239;units/kg per week.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Symptomatic anaemia in adults with non-myeloid malignancies receiving chemotherapy</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By subcutaneous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 450&#8239;units/kg once weekly for 4 weeks, dose to be given weekly as a single dose or in 3&#8211;7 divided doses, increase dose after 4 weeks (if a rise in haemoglobin of at least 1&#8239;g/100&#8239;mL not achieved), increased to 900&#8239;units/kg once weekly, dose to be given weekly as a single dose or in 3&#8211;7 divided doses, if adequate response obtained reduce dose by 25&#8211;50%, discontinue treatment if haemoglobin concentration does not increase by at least 1&#8239;g/100&#8239;mL after 8 weeks of therapy (response unlikely). Reduce dose by approximately 25&#8211;50% if rise in haemoglobin concentration exceeds 2 g/100 mL over 4 weeks or if haemoglobin concentration exceeds 12&#8239;g/100&#8239;mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose. Discontinue approximately 4 weeks after ending chemotherapy; maximum 60&#8239;000&#8239;units per week.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">To increase yield of autologous blood (to avoid homologous blood) in predonation programme in moderate anaemia when blood-conserving procedures are insufficient or unavailable</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous injection or by subcutaneous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>(consult product literature).</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP96762\" outputclass=\"pregnancy\" parent=\"/drugs/epoetin-beta\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>No evidence of harm.</p>\n<p>Benefits probably outweigh risk of anaemia and of blood transfusion in pregnancy.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP96752\" outputclass=\"breastFeeding\" parent=\"/drugs/epoetin-beta\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Unlikely to be present in milk.</p>\n<p>Minimal effect on infant.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP96759\" outputclass=\"hepaticImpairment\" parent=\"/drugs/epoetin-beta\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturers advise caution in chronic hepatic failure.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP96773\" outputclass=\"nationalFunding\" rev=\"1.29\" parent=\"/drugs/epoetin-beta\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA323</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (November 2014)</p>\r\n<p>Erythropoiesis-stimulating agents (epoetin alfa, beta, theta and zeta, and darbepoetin alfa) are recommended, within their marketing authorisations, as options for treating anaemia in people with cancer who are having chemotherapy.</p>\r\n<p>If different erythropoiesis-stimulating agents are equally suitable, the product with the lowest acquisition cost for the course of treatment should be used.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA323\">www.nice.org.uk/TA323</xref>\n</sectiondiv>\n</sectiondiv>\r\n </section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP96720-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/epoetin-beta\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP96833\" title=\"Solution for injection\" namespace=\"/drugs/epoetin-beta/solution-for-injection\">Solution for injection</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78590\" namespace=\"/treatment-summaries/anaemias\" title=\"Anaemias\" count=\"1\" rel=\"backlink\">Anaemias</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34585\" namespace=\"/drug-classes/epoetins\" title=\"EPOETINS\" count=\"1\" rel=\"link\">EPOETINS</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP96833\" namespace=\"/drugs/epoetin-beta/solution-for-injection\" title=\"Solution for injection\" count=\"1\" rel=\"link\">Solution for injection</xref>\n</links>\n</topic>",
    "id": "PHP96720",
    "outputclass": "drug",
    "rev": "1.16",
    "type": "drug",
    "namespace": "/drugs/epoetin-beta",
    "basename": "epoetin-beta",
    "title": "EPOETIN BETA",
    "vtmid": "327623006",
    "drugClassification": [
        "Epoetins"
    ],
    "inheritsFromClass": [
        "EPOETINS"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Symptomatic anaemia associated with chronic renal failure",
                        "html": "Symptomatic anaemia associated with chronic renal failure"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous injection"
                    ],
                    "textContent": "By intravenous injection",
                    "html": "By intravenous injection"
                },
                "adult": [
                    {
                        "textContent": "Initially 20 units/kg 3 times a week for 4 weeks, increased in steps of 20 units/kg 3 times a week, according to response at intervals of 4 weeks, total weekly dose may be divided into daily doses; maintenance dose, initially reduce dose by half then adjust according to response at intervals of 1&#8211;2 weeks, total weekly maintenance dose may be given as a single dose or in 3 or 7 divided doses. Subcutaneous route preferred in patients not on haemodialysis. Reduce dose by approximately 25% if rise in haemoglobin concentration exceeds 2 g/100 mL over 4 weeks or if haemoglobin concentration approaches or exceeds 12 g/100 mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose; maximum 720 units/kg per week.",
                        "html": "<p>Initially 20&#8239;units/kg 3 times a week for 4 weeks, increased in steps of 20&#8239;units/kg 3 times a week, according to response at intervals of 4 weeks, total weekly dose may be divided into daily doses; maintenance dose, initially reduce dose by half then adjust according to response at intervals of 1&#8211;2 weeks, total weekly maintenance dose may be given as a single dose or in 3 or 7 divided doses. Subcutaneous route preferred in patients not on haemodialysis. Reduce dose by approximately 25% if rise in haemoglobin concentration exceeds 2&#8239;g/100&#8239;mL over 4 weeks or if haemoglobin concentration approaches or exceeds 12&#8239;g/100&#8239;mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose; maximum 720&#8239;units/kg per week.</p>"
                    },
                    {
                        "textContent": "Initially 40 units/kg 3 times a week for 4 weeks, then increased to 80 units/kg 3 times a week, then increased in steps of 20 units/kg 3 times a week if required, at intervals of 4 weeks; maintenance dose, initially reduce dose by half then adjust according to response at intervals of 1&#8211;2 weeks. Intravenous injection to be administered over 2 minutes. Subcutaneous route preferred in patients not on haemodialysis. Reduce dose by approximately 25% if rise in haemoglobin concentration exceeds 2 g/100 mL over 4 weeks or if haemoglobin concentration approaches or exceeds 12 g/100 mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose; maximum 720 units/kg per week.",
                        "html": "<p>Initially 40&#8239;units/kg 3 times a week for 4 weeks, then increased to 80&#8239;units/kg 3 times a week, then increased in steps of 20&#8239;units/kg 3 times a week if required, at intervals of 4 weeks; maintenance dose, initially reduce dose by half then adjust according to response at intervals of 1&#8211;2 weeks. Intravenous injection to be administered over 2 minutes. Subcutaneous route preferred in patients not on haemodialysis. Reduce dose by approximately 25% if rise in haemoglobin concentration exceeds 2&#8239;g/100&#8239;mL over 4 weeks or if haemoglobin concentration approaches or exceeds 12&#8239;g/100&#8239;mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose; maximum 720&#8239;units/kg per week.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Symptomatic anaemia in adults with non-myeloid malignancies receiving chemotherapy",
                        "html": "Symptomatic anaemia in adults with non-myeloid malignancies receiving chemotherapy"
                    }
                ],
                "specificity": {
                    "routes": [
                        "subcutaneous injection"
                    ],
                    "textContent": "By subcutaneous injection",
                    "html": "By subcutaneous injection"
                },
                "adult": [
                    {
                        "textContent": "Initially 450 units/kg once weekly for 4 weeks, dose to be given weekly as a single dose or in 3&#8211;7 divided doses, increase dose after 4 weeks (if a rise in haemoglobin of at least 1 g/100 mL not achieved), increased to 900 units/kg once weekly, dose to be given weekly as a single dose or in 3&#8211;7 divided doses, if adequate response obtained reduce dose by 25&#8211;50%, discontinue treatment if haemoglobin concentration does not increase by at least 1 g/100 mL after 8 weeks of therapy (response unlikely). Reduce dose by approximately 25&#8211;50% if rise in haemoglobin concentration exceeds 2 g/100 mL over 4 weeks or if haemoglobin concentration exceeds 12 g/100 mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose. Discontinue approximately 4 weeks after ending chemotherapy; maximum 60 000 units per week.",
                        "html": "<p>Initially 450&#8239;units/kg once weekly for 4 weeks, dose to be given weekly as a single dose or in 3&#8211;7 divided doses, increase dose after 4 weeks (if a rise in haemoglobin of at least 1&#8239;g/100&#8239;mL not achieved), increased to 900&#8239;units/kg once weekly, dose to be given weekly as a single dose or in 3&#8211;7 divided doses, if adequate response obtained reduce dose by 25&#8211;50%, discontinue treatment if haemoglobin concentration does not increase by at least 1&#8239;g/100&#8239;mL after 8 weeks of therapy (response unlikely). Reduce dose by approximately 25&#8211;50% if rise in haemoglobin concentration exceeds 2 g/100 mL over 4 weeks or if haemoglobin concentration exceeds 12&#8239;g/100&#8239;mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose. Discontinue approximately 4 weeks after ending chemotherapy; maximum 60&#8239;000&#8239;units per week.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "To increase yield of autologous blood (to avoid homologous blood) in predonation programme in moderate anaemia when blood-conserving procedures are insufficient or unavailable",
                        "html": "To increase yield of autologous blood (to avoid homologous blood) in predonation programme in moderate anaemia when blood-conserving procedures are insufficient or unavailable"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous injection or subcutaneous injection"
                    ],
                    "textContent": "By intravenous injection or by subcutaneous injection",
                    "html": "By intravenous injection or by subcutaneous injection"
                },
                "adult": [
                    {
                        "textContent": "(consult product literature).",
                        "html": "<p>(consult product literature).</p>"
                    }
                ]
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "No evidence of harm.\n\nBenefits probably outweigh risk of anaemia and of blood transfusion in pregnancy.",
                "html": "<p>No evidence of harm.</p><p>Benefits probably outweigh risk of anaemia and of blood transfusion in pregnancy.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Unlikely to be present in milk.\n\nMinimal effect on infant.",
                "html": "<p>Unlikely to be present in milk.</p><p>Minimal effect on infant.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturers advise caution in chronic hepatic failure.",
                "html": "<p>Manufacturers advise caution in chronic hepatic failure.</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA323",
                        "label": "www.nice.org.uk/TA323"
                    }
                ],
                "fundingIdentifier": "NICE TA323",
                "textContent": "Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (November 2014) Erythropoiesis-stimulating agents (epoetin alfa, beta, theta and zeta, and darbepoetin alfa) are recommended, within their marketing authorisations, as options for treating anaemia in people with cancer who are having chemotherapy. If different erythropoiesis-stimulating agents are equally suitable, the product with the lowest acquisition cost for the course of treatment should be used.\n\nwww.nice.org.uk/TA323",
                "html": "<p outputclass=\"title\">Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (November 2014)</p> <p>Erythropoiesis-stimulating agents (epoetin alfa, beta, theta and zeta, and darbepoetin alfa) are recommended, within their marketing authorisations, as options for treating anaemia in people with cancer who are having chemotherapy.</p> <p>If different erythropoiesis-stimulating agents are equally suitable, the product with the lowest acquisition cost for the course of treatment should be used.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA323\">www.nice.org.uk/TA323</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP96833",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78590",
                "label": "Anaemias",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "drugClass": [
            {
                "id": "PHP34585",
                "label": "EPOETINS",
                "type": "drugClass"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP96833",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    }
}